<DOC>
	<DOCNO>NCT00002947</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray source damage tumor cell . Giving radiation therapy different way may kill tumor cell . PURPOSE : Phase I trial study effectiveness indium In 111 pentetreotide treat patient refractory cancer .</brief_summary>
	<brief_title>Indium In 111 Pentetreotide Treating Patients With Refractory Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) , toxic effect , preliminary antitumor activity indium In 111 pentetreotide . OUTLINE : This dose escalation study . Patients receive indium In III pentetreotide ( OctreoScan ) IV day 1 . Imaging conducted day 3 6 . Treatment continue weekly total 4 course absence disease progression unacceptable toxicity . Cohorts least 3 patient receive escalate dos OctreoScan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 patient experience dose limit toxicity . Patients follow every 3 month first year , every 6 month thereafter . PROJECTED ACCRUAL : Up 35 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven malignancy alternate treatment available Measurable evaluable progressive disease Somatostatin receptor present tumor uptake demonstrate diagnostic scan OctreoScan PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm3 Absolute neutrophil count least 1,500/mm3 Hepatic : Total bilirubin great 2.0 mg/dL Renal : Creatinine clearance least 40 mL/min Other : No active infection Not HIV positive No coexist medical condition Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior wide field radiation therapy Surgery : Recovery prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>prolactin-producing pituitary tumor</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>WDHA syndrome</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>childhood Langerhans cell histiocytosis</keyword>
	<keyword>metastatic pheochromocytoma</keyword>
	<keyword>recurrent pheochromocytoma</keyword>
	<keyword>pulmonary carcinoid tumor</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III neuroendocrine carcinoma skin</keyword>
	<keyword>recurrent neuroendocrine carcinoma skin</keyword>
</DOC>